Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· January 24, 2026

Grant Cardone: A home is a ‘terrible investment’ since it ‘ain’t your house.’ How to tap real estate without a mortgage

View original at finance.yahoo.com
Grant Cardone: A home is a ‘terrible investment’ since it ‘ain’t your house.’ How to tap real estate without a mortgage Ivan Apfel / Getty Images Moneywise and Yahoo Finance LLC may earn commission or revenue through links in the content below…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Raising rents from $1,000 to $1,200 on a property can generate $1,200,000 in value

    80% confidence
  • Look for properties where rents are below market ($1,000 vs $1,200), typically 1970-1980 built, owned by long-term owners who didn't raise rents

    80% confidence
  • Never buy a house to live in, but rent where you live and invest the difference in cash-flowing real estate

    80% confidence
  • Buying a home is a terrible investment because it doesn't provide cash flow, lacks significant tax write-offs, has no leverage, requires constant payment, and is never truly owned due to ongoing property taxes, insurance, and maintenance costs

    80% confidence
  • Ideal multifamily investment is 32 units because vacancy impact is minimized

    80% confidence
  • A house is not something that people should be buying. They should rent.

    80% confidence
  • Nearly 50% of Americans are making one big Social Security mistake

    80% confidence
  • People get emotional about homeownership and ignore the financial downsides

    80% confidence
  • Investors should own real estate that produces cash flow rather than a primary residence

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com